Tech Company Financing Transactions
Ethris Funding Round
Ethris closed a $15 million funding round on 2/25/2026. Investors included private investors.
Transaction Overview
Company Name
Announced On
2/25/2026
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The funding will support the advancement of Ethris's mRNA vaccine technology as a mucosal vaccine against pandemic influenza.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Semmelweisstr. 3
Planegg, 82152
Germany
Planegg, 82152
Germany
Phone
Website
Email Address
Overview
Based in Planegg just outside Munich, Germany, Ethris was founded by Dr. Carsten Rudolph and Prof. Christian Plank to establish messenger RNA (mRNA) as a new drug modality. As an mRNA pioneer, we are applying our unique, proprietary SNIM® RNA platform and our proprietary lipidoid nanoparticle (LNP) formulation and delivery platform to provide highly versatile, multi-route, multi-cargo delivery options that drive a range of drug candidates through proof-of-concept and into the clinic.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Carsten Rudolph
Chief Medical Officer
Thomas Langenickel
Chief Technical Officer
Christian Plank
VP - Bus. Development
Cliff Holloway
VP - Bus. Development
Christian Wawrzinek
Browse more venture capital transactions:
Prev: 2/25/2026: Chariot Defense venture capital transaction
Next: 2/25/2026: Prophet Security venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records on this site come from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs